Systemic treatment of newly diagnosed advanced epithelial ovarian cancer: From chemotherapy to precision medicine

• Published in: Critical reviews in oncology/hematology Vol. 158; p. 103209
• Main Authors: Perez-Fidalgo, J. Alejandro, Grau, Francisco, Fariñas, Lorena, Oaknin, Ana
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.02.2021
• Subjects: Antiangiogenics; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Carboplatin - therapeutic use; Carcinoma, Ovarian Epithelial - drug therapy; Chemotherapy; Female; Humans; Maintenance therapy; Neoplasm Recurrence, Local - drug therapy; Ovarian cancer; Ovarian Neoplasms - diagnosis; Ovarian Neoplasms - drug therapy; Paclitaxel; PARP inhibitors; Precision Medicine; Upfront therapy; Chemotherapy; Upfront therapy; Antiangiogenics; Maintenance therapy; PARP inhibitors; Ovarian cancer
• ISSN: 1040-8428; 1879-0461
• DOI: 10.1016/j.critrevonc.2020.103209

[Display omitted] Despite optimal first-line treatment based on debulking surgery and platinum-paclitaxel chemotherapy, most of the patients with advanced ovarian cancer (AOC) will eventually relapse. Over the last decades, different strategies have been assessed to improve AOC patients’ outcomes in the front-line treatment. However, first line treatment landscape of AOC had not undergone major changes until the last three years. In the present review, we will navigate through the different therapeutic approaches developed in first-line AOC which range from variations in dose/administration via of conventional carboplatin-based chemotherapy to the incorporation of anti-angiogenic agents and PARP inhibitors.